ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » Systemic Lupus Erythematosus – Animal Models Poster

Date: Tuesday, October 23, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

Abstract Number: 2085
Response Gene to Complement-32 Promotes Kidney Damage in Immune Complex –Mediated Glomerulonephritis
Abstract Number: 2086
4-Phenylbutyric Acid Mediates Therapeutic Effect in Systemic Lupus Erythematosus: Observations in an Experimental Murine Lupus Model
Abstract Number: 2087
Kidney Tissue Damage in Mice with Single and Combined Abnormalities in Complement, Interferon and Apoptotic Cell Clearance
Abstract Number: 2088
Human TLR8 at the Interface between Innate and Adaptive Immunity in Systemic Lupus Erythematosus
Abstract Number: 2089
The Differential Impact of the Abrogation of the Costimulatory Molecule CD137 Ligand on Renal and Cerebral Manifestations in C57BL/6.Faslpr-/- mice
Abstract Number: 2090
Identification of a Role for Monocytes in Murine Lupus Associated Diffuse Alveolar Hemorrhage By Mass Cytometry
Abstract Number: 2091
Mucosal-Associated Invariant T (MAIT) Cells As a Potential Therapeutic Target for Systemic Lupus Erythematosus
Abstract Number: 2092
Glucocorticoid-Induced Leucine Zipper (GILZ) Is a Novel Checkpoint Regulator of Type I Interferon (IFN) Production in SLE
Abstract Number: 2093
Glucocorticoid-Induced Leucine Zipper (GILZ) Deficiency Worsens Autoimmunity in the Lyn-Deficient Murine Model of Lupus By Disinhibiting the Type I Interferon (IFN) Pathway
Abstract Number: 2094
Examining T Cell Exhaustion in Murine Systemic Lupus Erythematosus
Abstract Number: 2095
Neutralizing CXCL13 Attenuates Neuropsychiatric Disease in Lupus-Prone Mice
Abstract Number: 2096
Ectonucleotidase CD73 Suppresses Autoantibody Production and Arterial Vasculopathy in Murine Lupus
Abstract Number: 2097
Monotherapy with Filgotinib, a JAK1-Selective Inhibitor, Reduces Disease Severity and Alters Immune Cell Subsets in the NZB/W F1 Murine Model of Lupus
Abstract Number: 2098
NRF2 Downregulates Inflammation and Protects Against Autoimmune Lung Disease in Experimental Lupus
Abstract Number: 2099
Bruton’s Tyrosine Kinase (BTK) Inhibition Modulates Multiple Cell Types Instrumental in the Pathogenesis of Lupus Nephritis
Abstract Number: 2100
Topical Endocannabinoid Administration Protects MRL-Lpr/Lpr Mice from Cutaneous Lupus Erythematosus
Abstract Number: 2101
UV-Induced Skin Inflammation Is Exacerbated in Lupus-Prone Ro60 Knockout Female Mice with Interferon Priming
Abstract Number: 2102
Hyaluronic Acid Synthesis Inhibition Blocks Nephritis and Extends Lifespan in Mice Prone to Lupus
Abstract Number: 2103
Using a Drosophila Model to Unravel the Genetic Complexity of Systemic Lupus Erythematosus
Abstract Number: 2104
Glomerular and Tubular Transcriptional Profiles Reveal Gene Clusters Specific for Different Stages of Glomerulonephritis in NZM2328 Mice
Abstract Number: 2105
Genetic Analysis of a Drosophila Systemic Lupus Erythematosus Model Reveals Lupus Susceptibility Genes
Abstract Number: 2106
Angiotensin-Converting Enzyme Inhibitors Prevent Spatial Memory Impairment in a Mouse Model of Neuropsychiatric Lupus through LAIR1-Mediated Inhibition of Microglial Activation
Abstract Number: 2107
Lupus-Prone SLE1.2.3. Mice Exhibit Loss of Thymus-Derived CD4+CD25+Helios+ Tregs

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified ­­­presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2023 American College of Rheumatology